Reminder for Medpace Stock Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record and resources in this field.
- Investor Advisory: Investors are advised to carefully select legal counsel, avoiding firms that act merely as intermediaries, and instead choose attorneys with proven success in securities class actions to ensure their rights are effectively protected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 447.110
Low
462.00
Averages
569.17
High
660.00
Current: 447.110
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Holdings Class Action Lawsuit Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements during the class period, concealing its true backlog cancellation rates, which led investors to have overly optimistic growth expectations that could not sustain a 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong reputation in the field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the litigation process.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notification: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, which reduces the financial burden on investors and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements during the class period, concealing the true cancellation rates, which led investors to have overly optimistic growth expectations, resulting in losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Investors Alert: Class Action Lawsuit Deadlines
- Class Action Reminder: Holzer & Holzer LLC alerts investors about a class action lawsuit against Medpace Holdings, Inc. alleging significant false statements regarding its fourth-quarter 2025 book-to-bill ratio, with a deadline of June 8, 2026, for investors to apply as lead plaintiffs.
- Electrification Market Opportunity: The class action against Stellantis N.V. claims that the company failed to disclose its potential earnings growth in the expanding electrification market, urging affected investors to apply for lead plaintiff status by June 8, 2026, to protect their rights.
- AI Model Controversy: Upstart Holdings, Inc. faces a class action lawsuit alleging it did not disclose material facts related to its AI model “Model 22” between May and November 2025, with a similar deadline of June 8, 2026, for impacted investors to act.
- Commitment to Legal Services: Since its founding in 2000, Holzer & Holzer LLC has been dedicated to vigorously representing shareholders, recovering hundreds of millions of dollars for victims of corporate misconduct, showcasing its expertise and influence in securities litigation.
See More
Important Deadline for Medpace Shareholder Lawsuit Approaches
- Significant Shareholder Losses: Between April 22, 2025, and February 9, 2026, Medpace Holdings Inc. shares plummeted from $530.35 to $446.05, resulting in a loss of $84.30 per share and a decline exceeding 15.9%, highlighting serious issues with the company's financial transparency.
- Lead Plaintiff Application Deadline: Investors must file motions by June 8, 2026, to seek lead plaintiff status; those who miss this deadline can still participate as absent class members in any future settlements or judgments but will lose direct control over the litigation.
- No Legal Fees Required: Investors serving as lead plaintiffs incur no out-of-pocket costs, as attorney fees are only deducted from any recovery, which reduces the financial risk of participating in the lawsuit and encourages more shareholders to get involved.
- Court Review Process: After the deadline, the United States District Court for the Southern District of Ohio will review all applications and appoint the most suitable lead plaintiff, a process expected to take several weeks, ensuring that the litigation is represented by shareholders with substantial financial interests.
See More
Class Action Lawsuits Reminder for Shareholders
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action for failing to disclose that Latin American patients performed well on placebo, leading to the Phase 3 PROSERA study not meeting its primary endpoint, with shareholders encouraged to participate before the deadline.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is accused of overstating progress on its Texas Critical Data Centers project and engaging in fraudulent schemes, prompting shareholders to act before the deadline.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is under scrutiny for misleading statements regarding its projected book-to-bill ratio for Q4 2025, with investors advised to participate in the lawsuit before the deadline.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses during the relevant periods to contact them to understand their legal rights and steps to participate in the class actions.
See More
Medpace Class Action Lawsuit Notification
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false and misleading statements during the class period, concealing the true state of Medpace's backlog cancellation rate, which led investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its successful track record and expertise in the field.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure effective representation in the lawsuit and avoid inexperienced intermediaries.
See More
Medpace Holdings Class Action Lawsuit Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements during the class period, concealing its true backlog cancellation rates, which led investors to have overly optimistic growth expectations that could not sustain a 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong reputation in the field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the litigation process.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notification: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, which reduces the financial burden on investors and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements during the class period, concealing the true cancellation rates, which led investors to have overly optimistic growth expectations, resulting in losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Investors Alert: Class Action Lawsuit Deadlines
- Class Action Reminder: Holzer & Holzer LLC alerts investors about a class action lawsuit against Medpace Holdings, Inc. alleging significant false statements regarding its fourth-quarter 2025 book-to-bill ratio, with a deadline of June 8, 2026, for investors to apply as lead plaintiffs.
- Electrification Market Opportunity: The class action against Stellantis N.V. claims that the company failed to disclose its potential earnings growth in the expanding electrification market, urging affected investors to apply for lead plaintiff status by June 8, 2026, to protect their rights.
- AI Model Controversy: Upstart Holdings, Inc. faces a class action lawsuit alleging it did not disclose material facts related to its AI model “Model 22” between May and November 2025, with a similar deadline of June 8, 2026, for impacted investors to act.
- Commitment to Legal Services: Since its founding in 2000, Holzer & Holzer LLC has been dedicated to vigorously representing shareholders, recovering hundreds of millions of dollars for victims of corporate misconduct, showcasing its expertise and influence in securities litigation.
See More
Important Deadline for Medpace Shareholder Lawsuit Approaches
- Significant Shareholder Losses: Between April 22, 2025, and February 9, 2026, Medpace Holdings Inc. shares plummeted from $530.35 to $446.05, resulting in a loss of $84.30 per share and a decline exceeding 15.9%, highlighting serious issues with the company's financial transparency.
- Lead Plaintiff Application Deadline: Investors must file motions by June 8, 2026, to seek lead plaintiff status; those who miss this deadline can still participate as absent class members in any future settlements or judgments but will lose direct control over the litigation.
- No Legal Fees Required: Investors serving as lead plaintiffs incur no out-of-pocket costs, as attorney fees are only deducted from any recovery, which reduces the financial risk of participating in the lawsuit and encourages more shareholders to get involved.
- Court Review Process: After the deadline, the United States District Court for the Southern District of Ohio will review all applications and appoint the most suitable lead plaintiff, a process expected to take several weeks, ensuring that the litigation is represented by shareholders with substantial financial interests.
See More
Class Action Lawsuits Reminder for Shareholders
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action for failing to disclose that Latin American patients performed well on placebo, leading to the Phase 3 PROSERA study not meeting its primary endpoint, with shareholders encouraged to participate before the deadline.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is accused of overstating progress on its Texas Critical Data Centers project and engaging in fraudulent schemes, prompting shareholders to act before the deadline.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is under scrutiny for misleading statements regarding its projected book-to-bill ratio for Q4 2025, with investors advised to participate in the lawsuit before the deadline.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses during the relevant periods to contact them to understand their legal rights and steps to participate in the class actions.
See More
Medpace Class Action Lawsuit Notification
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false and misleading statements during the class period, concealing the true state of Medpace's backlog cancellation rate, which led investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its successful track record and expertise in the field.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure effective representation in the lawsuit and avoid inexperienced intermediaries.
See More
